Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg.
This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
Take 1 tablet of this drug 5/1000 mg extended-release tablet once daily.
Patients taking this drug 2.5/1000 mg extended-release tablets should take 2 tablets together once daily.
1. Patients not currently receiving metformin:
The initial total daily dose of this drug is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg.
2. Patients receiving metformin
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride.
- For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this drug is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia.
- When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate, if necessary.
- When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should be equivalent to the patient's current doses of linagliptin and extended-release metformin hydrochloride.
Renal impairment
Because dose adjustment based on renal function is necessary, assessment of renal function is recommended before treatment with this drug and periodically thereafter.
No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2].
In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis.
The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this drug should be discontinued immediately.
Improvement of glycemic control in patients with type 2 diabetes mellitus
View approved original textHide original text
This medication helps control blood sugar for patients with type 2 diabetes who use linagliptin and metformin together. It can effectively manage blood sugar when used in conjunction with dietary management and exercise therapy. It helps maintain stable blood sugar levels for diabetes management.
How to take
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg.
This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
Take 1 tablet of this drug 5/1000 mg extended-release tablet once daily.
Patients taking this drug 2.5/1000 mg extended-release tablets should take 2 tablets together once daily.
1. Patients not currently receiving metformin:
The initial total daily dose of this drug is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg.
2. Patients receiving metformin
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride.
- For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this drug is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia.
- When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate, if necessary.
- When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should be equivalent to the patient's current doses of linagliptin and extended-release metformin hydrochloride.
Renal impairment
Because dose adjustment based on renal function is necessary, assessment of renal function is recommended before treatment with this drug and periodically thereafter.
No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2].
In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis.
The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this drug should be discontinued immediately.
Precautions
This medication contains two ingredients, metformin hydrochloride and linagliptin.
Firstly, this medication can rarely cause a serious condition called lactic acidosis, which can lead to dangerous levels of lactic acid in the body and should be approached with caution.
This medication should not be used in certain patients, such as those who are allergic to this medication, those with type 1 diabetes, severely impaired kidney function, severe liver dysfunction, acute alcohol intoxication, and severe heart diseases should avoid its use.
Additionally, since this medication can cause hypoglycemia, it is necessary to monitor blood sugar closely when taken with insulin or sulfonylureas, and reduce the doses of those medications if necessary.
Patients with impaired kidney function should have their kidney function regularly checked before and after taking this medication, and it should not be used if kidney function is very poor.
If an iodinated contrast agent is administered during radiological tests, kidney damage can occur, necessitating the discontinuation of this medication for a certain period before and after the test, resuming only after kidney function has recovered.
Patients scheduled for surgery should stop taking this medication 48 hours before the surgery and resume only after kidney function and condition have stabilized post-surgery.
Women who are pregnant or planning to become pregnant are advised to avoid taking this medication, and it should not be used during breastfeeding.
This medication should be swallowed whole and not broken or chewed, and while the tablet coating may appear in feces, this is normal.
If there are sudden severe abdominal pains, vomiting, or skin blisters or rashes during the course of treatment, consult a physician immediately, and the medication should be discontinued if such symptoms occur.
This medication can reduce vitamin B12 levels, so those on long-term treatment should have their vitamin B12 levels checked and supplemented if necessary.
This medication can interact with other drugs, so if there are other medications being taken simultaneously, it is vital to inform a doctor or pharmacist, especially with those that can affect kidney function.
Elderly patients often experience decreased kidney function, so kidney function should be frequently monitored while taking this medication, and doses adjusted if needed.
In case of overdose, there is a risk of lactic acidosis and immediate medical treatment is required, with blood dialysis generally being the most effective treatment method.
Side effects
Severe lactic acidosis
hypoglycemia
nasopharyngitis
hypersensitivity reactions
angioedema
urticaria
lactic acidosis
abnormal vitamin B12 absorption test
hypoglycemia
taste disturbances
Show 116 moreCollapse
cough
decreased appetite
diarrhea
constipation
nausea
pancreatitis
vomiting
abdominal pain
oral ulcers
abnormal liver function tests
hepatitis
pruritus
erythema
rash
pemphigoid-like lesions
severe joint pain with disability
rhabdomyolysis
increased lipase
increased amylase
constipation
upper abdominal pain
enterocolitis
intestinal obstruction
gastritis
herpes zoster
cystitis
acute pyelonephritis
bronchitis
vestibular neuronitis
sepsis
pneumonia
decreased appetite
dehydration
hyperglycemia
cerebral infarction
stuttering
Alzheimer's type dementia
chest pain
fever
facial swelling
fatigue
chronic obstructive pulmonary disease
asthma
diabetic foot disease
skin lesions
liver metastasis
acute leukemia
basal cell carcinoma
non-small cell lung cancer
malignant pericardial effusion
gastric cancer
colorectal cancer
pancreatic cancer
meniscus injury
pneumoconiosis
congestive heart failure
angina
acute myocardial infarction
unstable angina
cardiac arrest
diabetic retinopathy
acute kidney injury
end-stage renal disease
acute cholangitis
acute cholecystitis
cholangitis
dizziness
kidney transplant failure
anxiety
mood disorder
insomnia
depression
contusion
bone contusion
concussion
bone fracture
hand fracture
palpitations
dry eyes
glaucoma
cataract
ocular discomfort
allergic conjunctivitis
polyuria
proteinuria
hematuria
hypotension
flushing
hepatic steatosis
cholelithiasis
hearing loss
erectile dysfunction
goiter
anemia
nausea
gastroesophageal reflux disease
gastritis
dizziness
sensory loss
chest discomfort
weakness
epistaxis
oropharyngeal pain
voice disorder
nosebleed
vocal cord polyp
dyslipidemia
hypercholesterolemia
male pattern baldness
hyperhidrosis
dermatitis
anxiety
confusion
nocturia
dermatitis
hypertension
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a tightly closed container to protect it from air and moisture, at a safe temperature between 1 degree Celsius and 30 degrees Celsius.
Storing it this way helps maintain the medication's effectiveness and prevents degradation.
Appearance and packaging
Appearance
Yellow oval sustained release film-coated tablets
Package unit
30 tablets per bottle
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.